BBLGW

Bone Biologics Corp Warrants represent the right to purchase shares of Bone Biologics Corp common stock at a predetermined exercise price. These warrants were issued as part of previous financing transactions and provide holders with leverage to the company's equity performance. Each warrant typically allows the holder to purchase one share of common stock at a specified strike price within a defined time period. As financial instruments tied to Bone Biologics Corp, these warrants' value is derived from the underlying stock price. Warrants become more valuable as the stock price rises above the exercise price, offering investors potential upside participation. However, if the stock price remains below the exercise price at expiration, the warrants expire worthless. Warrants trade separately from the common stock and appeal to investors seeking leveraged exposure to the company's prospects. Bone Biologics is a development-stage biotechnology company focused on bone regeneration therapeutics, particularly its NELL-1/DBX product candidate for spinal fusion procedures. The company's technology is based on UCLA research involving the NELL-1 protein for bone formation. Warrant holders gain value if the company successfully advances its clinical programs, achieves regulatory milestones, or experiences positive business developments that drive the stock price higher. These instruments carry higher risk but offer greater potential returns compared to holding the common stock directly.